SKX-16 (Luliconazole 10% Solution) for Toenail Fungus

"This trial is recruiting 20 individuals with a particular structure of toe nails aged 18-65. Criteria for enrolment include: persons of any gender, ethnicity and age bracket; visible signs of distal subungual onychomycosis in both great toenails plus at least four additional toes; evidence of fungal hyphae through KOH wet mount testing and positive fungi culture from one or more great toenails; serum creatinine levels lower than the upper limit of normal (ULN); AST/SGOT, ALT/SGPT, total bilirubin readings below ULN; female participants must"

"This research initiative has concluded its patient recruitment and the trial was originally posted on September 13th 2021, with a final edit made on June 13th 2022. There are 9 studies that remain active for "structure of nail of toe" and 1 study where SKX-16 (Luliconazole 10% Solution) is being utilized."

"Currently, there is just one active clinical trial focusing on SKX-16 (Luliconazole 10% Solution) and it has not yet entered Phase 3. Primarily located in College Station, Texas, the research for this drug is being conducted at a single location."

"This Phase 1 trial has limited evidence of both efficacy and safety, so our team assigned SKX-16 (Luliconazole 10% Solution) a rating of 1."

"This clinical trial requires that participants be at least 18 years old and not exceed the age of 65."

"According to clinicaltrials.gov, this experiment is no longer recruiting patients; the original post was published in September 2021 and then last updated in June 2022. Even though there are no active recruitment efforts at this time, 10 other trials have open slots for participants."

"Presently, there is only one active clinical trial for SKX-16 (Luliconazole 10% Solution) occuring in a single city and country. Initially conducted in 2021 by SATO Pharmaceutical Co., Ltd., the Phase 1 drug approval stage concluded with 20 participants. Since then, 6 more trials have been successfully completed."